Johnson and Johnson is a drug company.

April 2007 - Johnson & Johnson's bladder drug Ditropan needs stronger cautions about the risk of hallucination and similar problems in children and older patients.

December 2006 - A new once-a-day treatment for schizophrenia derived from the active ingredient in Johnson & Johnson blockbuster schizophrenia treatment Risperdal. The pill, called Invega, is the first new schizophrenia treatment to win U.S. Food and Drug Administration approval since 2003, according to Johnson and Johnson. Schizophrenia is a chronic, disabling mental disorder that affects more than 2 million Americans. Symptoms include hallucinations, delusions, disordered thinking, movement disorders, social withdrawal and cognitive deficits, such difficulty with perception, memory or abstract thinking. The new treatment is designed to deliver paliperidone -- the active ingredient in Risperdal -- through a technology that allows the drug to remain in the body over a longer period of time.

October 2006 - The lawsuits, filed in San Francisco Superior Court, name as defendants the drug’s manufacturer, Ortho-McNeil Pharmaceutical Co., a Titusville, N.J.-based subsidiary of Johnson & Johnson; and San Francisco-based distributor McKesson Corp. The plaintiffs seek unspecified monetary damages. Approved by the U.S. Food and Drug Administration in 2001, Ortho Evra is a birth control patch that delivers the hormones estrogen and progestin directly into the bloodstream through the skin. The lawsuit claims that Ortho-McNeil failed to properly investigate the product’s safety and deceived the public about the severity of potential side effects, including strokes and severe blood clots.

Additional links on this website
Joint formula product
Joint Power Rx product